Solomon Dworsky

Volume 02 of 05

Transactions

$1.8B+ in announced transaction value across five transactions in healthcare technology and industrials.

eMed and Aon. Strategic investment, then a $200M round. NYSE: AON · Aug 2025 · Mar 2026

Aon, the global professional services firm, made a strategic investment in eMed to scale its GLP-1 population health platform. A $200M round followed at a valuation above $2B. Read onClose

Role. Issuer-side diligence workstreams and investor materials across both transactions. Owned the data room end to end, from the diligence tracker sent to the investor’s integration lead through the post-close variance report.

Aon announcement, August 2025 · Round announcement, March 2026, lead investor Aon Consulting. Per-investor allocations are not disclosed in either release.

eMed acquires Nomi Pharma. 2026 · Closed 32 days from first contact

eMed acquired a turnkey mail-order pharmacy with 44 state licenses from owners winding down operations, closed 32 days from first contact. Read onClose

Role. Led buy-side execution end to end. Wrote the investment committee memo and the letter of intent, built the contract and liability registers, and ran the daily standup with outside regulatory counsel through integration.

Science 37 take-private. $38M. NASDAQ: SNCE · 2024

eMed took Science 37 private for $38M, a de-SPAC that had listed near $1B, in an all-cash tender offer for all outstanding shares. Read onClose

Role. Managed the take-private, underwrote SG&A rationalization, and built a standalone DCF and comparables valuation. Diligence and process logistics: management presentation, customer reference calls, merger-agreement debrief with outside counsel, and the pre-closing call with the target’s CEO and General Counsel.

Two years post-close, owned the valuation package end to end through review: comparable universe, ten-year DCF, sensitivities, and the board deck.

Completion announcement, March 2024

Babylon Health UK. Acquired out of administration in 19 days. 2023

eMed acquired the UK operations of Babylon Health, a former $2B unicorn, out of Alvarez & Marsal administration in 19 days. Read onClose

Role. Led financial and platform diligence on the acquisition. The assets formed eMed UK.

The hard parts were structural rather than financial. A cross-border insolvency ran to the administrator’s timetable rather than the buyer’s. A regulated clinical operation could not pause while the deal was negotiated. The carve-out perimeter excluded the flagship NHS service.

Coverage: MobiHealthNews, September 2023

Zurn Water Solutions combines with Elkay. $1.56B all-stock. NYSE: ZWS · Prior role · 2022

Zurn Water Solutions combined with Elkay Manufacturing in an all-stock transaction, creating a water and building materials platform. Read onClose

Role. A first-year analyst seat, in a prior role. Executed diligence and HSR workstreams, and built the share-conversion model.

Completion announcement, June 2022

← Back to the shelf

Other volumes

Background Projects Work Examples Perspectives

Contact

Solomon Dworsky · Miami, Florida

Email LinkedIn Resume, PDF

Transaction work in healthcare technology. Applied AI in the investment process.